| John F O'toole, MD | |
|
2500 Metrohealth Dr, Rammelkamp R-460, Cleveland, OH 44109-1900 | |
| (216) 778-5790 | |
| (216) 778-2338 |
| Full Name | John F O'toole |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 26 Years |
| Location | 2500 Metrohealth Dr, Cleveland, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700968617 | NPI | - | NPPES |
| 242239 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 35090714 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cleveland Clinic | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
As Covid-19 infections soar across the U.S., some states are tightening restrictions and reinstituting quarantine measures to slow the virus' spread.
In order to make meaningful gains in cardiovascular disease care, primary care medical practices should adopt a set of care improvements specific to their practice size and type, according to a new study from the national primary care quality improvement initiative EvidenceNOW.
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
Patients with hypertension whose blood pressure cannot be brought down to safe levels despite taking three or more medications may have some relief coming their way. An innovative, first-of-its-kind clinical trial for a device representing a dramatic shift in treatment approaches for the toughest-to-treat patients is currently being conducted at NewYork-Presbyterian Hospital.
› Verified 2 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
As Covid-19 infections soar across the U.S., some states are tightening restrictions and reinstituting quarantine measures to slow the virus' spread.
In order to make meaningful gains in cardiovascular disease care, primary care medical practices should adopt a set of care improvements specific to their practice size and type, according to a new study from the national primary care quality improvement initiative EvidenceNOW.
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
Patients with hypertension whose blood pressure cannot be brought down to safe levels despite taking three or more medications may have some relief coming their way. An innovative, first-of-its-kind clinical trial for a device representing a dramatic shift in treatment approaches for the toughest-to-treat patients is currently being conducted at NewYork-Presbyterian Hospital.
› Verified 2 days ago
| Entity Name | The Metrohealth System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053353896 PECOS PAC ID: 8628982949 Enrollment ID: O20031119000355 |
News Archive
As Covid-19 infections soar across the U.S., some states are tightening restrictions and reinstituting quarantine measures to slow the virus' spread.
In order to make meaningful gains in cardiovascular disease care, primary care medical practices should adopt a set of care improvements specific to their practice size and type, according to a new study from the national primary care quality improvement initiative EvidenceNOW.
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
Patients with hypertension whose blood pressure cannot be brought down to safe levels despite taking three or more medications may have some relief coming their way. An innovative, first-of-its-kind clinical trial for a device representing a dramatic shift in treatment approaches for the toughest-to-treat patients is currently being conducted at NewYork-Presbyterian Hospital.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John F O'toole, MD 2500 Metrohealth Dr, Rammelkamp R-460, Cleveland, OH 44109-1900 Ph: (216) 778-5790 | John F O'toole, MD 2500 Metrohealth Dr, Rammelkamp R-460, Cleveland, OH 44109-1900 Ph: (216) 778-5790 |
News Archive
As Covid-19 infections soar across the U.S., some states are tightening restrictions and reinstituting quarantine measures to slow the virus' spread.
In order to make meaningful gains in cardiovascular disease care, primary care medical practices should adopt a set of care improvements specific to their practice size and type, according to a new study from the national primary care quality improvement initiative EvidenceNOW.
A.P. Pharma, a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of approximately $8.1 million, and a second tranche of common stock with proceeds of approximately $5 million.
Patients with hypertension whose blood pressure cannot be brought down to safe levels despite taking three or more medications may have some relief coming their way. An innovative, first-of-its-kind clinical trial for a device representing a dramatic shift in treatment approaches for the toughest-to-treat patients is currently being conducted at NewYork-Presbyterian Hospital.
› Verified 2 days ago
Amir Razavi, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Dr. Francois Fadell, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 18200 Lorain Ave, Moll Cancer Center At Fairview- Respiratory Institute, Cleveland, OH 44111 Phone: 216-444-6503 | |
Sana Hasan, DO Nephrology Medicare: Accepting Medicare Assignments Practice Location: Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195 Phone: 330-721-5700 | |
Catherine Frakes Vozzo, DO Nephrology Medicare: Not Enrolled in Medicare Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 216-444-4444 Fax: 216-445-6290 | |
Tarek Ashour, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave # Q7, Cleveland, OH 44195 Phone: 216-444-5040 | |
Mrs. Efewongbe Benedicta Oleghe, Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2351 E 22nd Street, St Vincent's Charity Medical Center, Cleveland, OH 44115 Phone: 216-363-2725 | |
Dr. Toufik Z. Madhun, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave Dept Of, Cleveland, OH 44106 Phone: 216-844-1000 |